UTHR News and Press, United Therapeutics Corporation From 05/23/22

Commercial-stage biotech, United Therapeutics (NASDAQ:UTHR) and its partner MannKind (MNKD) are trading sharply higher on Monday after the FDA announced the approval of their lung disease therapy Tyvaso DPI. Accordingly, the drug-device combination is authorized to treat the pulmonary arteria...

United Therapeutics Corporation (UTHR) Q1 2022 Results Conference Call May 04, 2022 09:00 AM ET Company Participants Dewey Steadman - Head, IR Martine Rothblatt - Chairperson, CEO Michael Benkowitz - President, COO Leigh Peterson - SVP, Product Development Patrick Poisson - EVP, Technical Ope...

United Therapeutics press release (NASDAQ:UTHR): Q1 GAAP EPS of $5.03 beats by $1.96. Revenue of $461.9M (+21.8% Y/Y) beats by $41.88M. “With this positive momentum, we continue to work toward reaching 6,000 patients on Tyvaso therapy by the end of 2022 and 25,000 patients on our thera...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2022. Total revenue in the first quarter of 2022 grew 22% year-over-year to $461.9 million, compared to $379.1 million in the first quarter...

United Therapeutics (NASDAQ:UTHR) is scheduled to announce Q1 earnings results on Wednesday, May 4th, before market open. The consensus EPS Estimate is $3.65 (+4.6% Y/Y) and the consensus Revenue Estimate is $420.02M (+10.8% Y/Y). Over the last 2 years, UTHR has beaten EPS estimates 75% of th...

Mini-symposia to focus on long-term extension data for the Tyvaso ® INCREASE study, the ralinepag phase 2 study, and the Orenitram ® FREEDOM-EV study Poster presentations touch on real-world treprostinil use, Tyvaso DPI™, and other treprostinil clinica...

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2022 financial results before the market opens on Wednesday, May 4, 2022. United Therapeutics will host a public webcast Wednesday, May 4, 2022, at 9:00 a.m. Eastern Time. The webcas...

In subjects with PAH, transition from Tyvaso ® to Tyvaso DPI™ demonstrated safety and tolerability with significant improvements in six-minute walk distance, device preference and satisfaction, and patient reported outcomes Tyvaso DPI safety confirmed through 5...

The first person to receive a heart transplant from a pig has died on Tuesday after two months from the landmark surgery at the University of Maryland Medical Center, the hospital announced Wednesday. The heart used in the groundbreaking operation came from United Therapeutics (UTHR -0.2%), a...

United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update on the company’s business during a fireside chat session at the Oppenheimer 32 nd Annual Healthcare Conference. T...